PU.1 expression is restored upon treatment of chronic myeloid leukemia patients

被引：18

作者：

Albajar, Marta ^{[1
,2
,3
]}

Gutierrez, Pilar ^{[1
,2
]}

Richard, Carlos ^{[3
]}

Rosa-Garrido, Manuel ^{[1
,2
]}

Teresa Gomez-Casares, M. ^{[4
]}

Steegmann, Juan L. ^{[5
]}

Leon, Javier ^{[1
,2
]}

Dolores Delgado, M. ^{[1
,2
]}

机构：

[1] Univ Cantabria, CSIC, IDICAN, Dept Biol Mol,Fac Med, Santander 39011, Spain

[2] Univ Cantabria, CSIC, IDICAN, Fac Med,IBBTEC, Santander 39011, Spain

[3] Hosp Univ Marques Valdecilla IFIMAV, Serv Hematol, Santander, Spain

[4] Hosp Dr Negrin Las Palmas de Gran Canaria, Serv Hematol, Las Palmas Gran Canaria, Spain

[5] Hosp Univ Princesa, Serv Hematol, Madrid, Spain

来源：

CANCER LETTERS | 2008年 / 270卷 / 02期

关键词：

PU.1; CML patients; Interferon-alpha; Imatinib;

D O I：

10.1016/j.canlet.2008.05.024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The PU.1 transcription factor is a crucial regulator of hematopoiesis which expression is altered in various leukemic processes. Our previous work in chronic myeloid leukemia (CML) cells demonstrated that interferon-alpha upregulated PU.1 expression. Here we show that expression of PU.1 is severely impaired in patients with CML at diagnosis. However, the PU.1 suppression is abrogated in patients in remission, after interferon-alpha or imatinib treatment. These effects are not found in patients with other myeloproliferative diseases such as polycythemia vera or essential thrombocythemia. PU.1 could, therefore, be used as an additional marker of the response to the treatment of the CML. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：328 / 336

页数：9

共 31 条

[1]

Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].

Capdeville, R ;

Buchdunger, E ;

Zimmermann, J ;

Matter, A .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502

[2]

PU. 1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain [J].

Cook, WD ;

McCaw, BJ ;

Herring, C ;

John, DL ;

Foote, SJ ;

Nutt, SL ;

Adams, JM .

BLOOD, 2004, 104 (12) :3437-3444

[3]

Is PU.1 a dosage-sensitive regulator of haemopoietic lineage commitment and leukaemogenesis? [J].

Dakic, Aleksandar ;

Wu, Li ;

Nutt, Stephen L. .

TRENDS IN IMMUNOLOGY, 2007, 28 (03) :108-114

[4]

The molecular biology of chronic myeloid leukemia [J].

Deininger, MWN ;

Goldman, JM ;

Melo, JV .

BLOOD, 2000, 96 (10) :3343-3356

[5]

Spi-1/PU.1 proto-oncogene induces opposite effects on monocytic and erythroid differentiation of K562 cells [J].

Delgado, MD ;

Gutiérrez, P ;

Richard, C ;

Cuadrado, MA ;

Moreau-Gachelin, F ;

León, J .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 252 (02) :383-391

[6]

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[7]

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program [J].

Gabert, J ;

Beillard, E ;

van der Velden, VHJ ;

Bi, W ;

Grimwade, D ;

Pallisgaard, N ;

Barbany, G ;

Cazzaniga, G ;

Cayuela, JM ;

Cavé, H ;

Pane, F ;

Aerts, JLE ;

De Micheli, D ;

Thirion, X ;

Pradel, V ;

González, M ;

Viehmann, S ;

Malec, M ;

Saglio, G ;

van Dongen, JJM .

LEUKEMIA, 2003, 17 (12) :2318-2357

[8]

Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells [J].

Gutierrez, P ;

Delgado, MD ;

Richard, C ;

MoreauGachelin, F ;

Leon, J .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 240 (03) :862-868

[9]

PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis [J].

Huang, Gang ;

Zhang, Pu ;

Hirai, Hideyo ;

Elf, Shannon ;

Yan, Xiaomei ;

Chen, Zhao ;

Koschmieder, Steffen ;

Okuno, Yutaka ;

Dayaram, Tajhal ;

Growney, Joseph D. ;

Shivdasani, Ramesh A. ;

Gilliland, D. Gary ;

Speck, Nancy A. ;

Nimer, Stephen D. ;

Tenen, Daniel G. .

NATURE GENETICS, 2008, 40 (01) :51-60

[10]

The paradox of response and survival in cancer therapeutics [J].

Huff, CA ;

Matsui, W ;

Smith, BD ;

Jones, RJ .

BLOOD, 2006, 107 (02) :431-434

← 1 2 3 4 →